Lyell Immunopharma, Inc. LYEL
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Lyell Immunopharma, Inc. (LYEL) is a healthcare company listed in the US with a market value of about $352M. In the twelve months to September 30, 2026 it had revenue of $15000 and net income of -$255M, a net margin of -1701066.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -66% a year, a 5-year average ROIC of -39%.
About Lyell Immunopharma
Lyell Immunopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $657000 in 2019 to $36000 in 2025, a decline of about 38.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 38% over three years (dilution for shareholders). It spends 440764% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15000 | $36000 | $61000 | $130000 | $85M | $11M | $8M | $657000 |
| Net income | -$255M | -$274M | -$343M | -$235M | -$183M | -$250M | -$204M | -$129M |
| Free cash flow | -$140M | -$151M | -$163M | -$166M | -$194M | -$192M | -$212M | $23M |
| EPS (diluted) | $-12.56 | $-16.06 | $-26.23 | $-18.70 | $-14.80 | $-36.80 | $-313.80 | $-0.48 |
| Net margin | -1701066.7% | -762400.0% | -562300.0% | -180500.0% | -216.2% | -2349.5% | -2636.3% | -19692.1% |
| ROIC | — | -71.1% | -64.1% | -27.2% | -16.4% | -17.0% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $37.62, 163% above the current price; targets range from $12.00 to $49.00; the consensus rating is “Buy”; expected EPS is $-6.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Lyell Immunopharma pay a dividend?
Not currently.
Is Lyell Immunopharma a good stock to buy?
We do not give buy or sell advice. Lyell Immunopharma scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.